Although Ab4 and patritumab did not inhibit cellular growth of MCF7 breast cancer cells in the medium containing 7%-FBS, both mAbs significantly inhibited the viability of MCF7 cells in the presence of erlotinib (HER1 inhibitor) (Figure 7E). This evidence concerns the gene EGFR and breast cancer.